Table IV.
Univariate and multivariate analyses to detect independent prognostic factors for OS.
| Univariate | Multivariate | ||||
|---|---|---|---|---|---|
| Variable | No. | Median survival, days | P-value | HR (95% CI) | P-value |
| Age, years | 0.073 | ||||
| <64 | 32 | 292 | |||
| ≥64 | 40 | 271 | |||
| Sex | 0.801 | ||||
| Male | 40 | 270 | |||
| Female | 32 | 292 | |||
| Diameter, mm | 0.399 | ||||
| <28 | 27 | 391 | |||
| ≥28 | 45 | 251 | |||
| Stage | <0.001 | 2.31 (0.91–5.90) | 0.078 | ||
| Locally advanced | 20 | 641 | |||
| Metastatic | 52 | 249 | |||
| First-line regimen | <0.001 | 0.25 (0.09–0.69) | 0.007 | ||
| Combination therapy | 24 | 641 | |||
| Monotherapy | 48 | 241 | |||
| CEA, ng/ml | 0.268 | 1.19 (0.52–2.73) | 0.680 | ||
| <5.0 | 43 | 292 | |||
| ≥5.0 | 29 | 251 | |||
| CA19-9, U/ml | 0.040 | 1.67 (0.68–4.11) | 0.263 | ||
| <1,772 | 40 | 376 | |||
| ≥1,772 | 32 | 247 | |||
| NLR | <0.001 | 2.18 (0.88–5.38) | 0.092 | ||
| <4.0 | 43 | 392 | |||
| ≥4.0 | 29 | 206 | |||
| PLR | 0.004 | 0.99 (0.47–2.10) | 0.984 | ||
| <182.0 | 38 | 391 | |||
| ≥182.0 | 34 | 236 | |||
| PNI | 0.013 | 0.52 (0.23–1.19) | 0.123 | ||
| <45.2 | 39 | 249 | |||
| ≥45.2 | 33 | 376 | |||
| mGPS | <0.001 | 26.16 (5.22–131.10) | <0.001 | ||
| 0, 1 | 63 | 342 | |||
| 2 | 9 | 97 | |||
| CONUT score | 0.016 | 0.69 (0.29–1.67) | 0.413 | ||
| <3 | 42 | 368 | |||
| ≥3 | 24 | 249 | |||
OS, overall survival; HR, hazard ratio; CEA, carcinoembryonic antigen; CA19-9, cancer antigen 19-9; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; mGPS, modified Glasgow prognostic score; CONUT, controlling nutritional status.